Unclaimed brand
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#F08D34
Jaffa
240, 141, 52
28, 86, 57
0, 41, 78, 6
#FECDA5
Flesh
254, 205, 165
27, 98, 82
0, 19, 35, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
Imugene is a clinical stage immuno-oncology company dedicated to developing innovative treatments for cancer patients. Their mission is to activate the immune system of cancer patients to identify and eradicate tumors, bringing effective new options to those in need. Imugene offers a range of treatments, including their lead candidate CF33, a chimeric vaccinia virus developed by Professor Yuman Fong, and HER-Vaxx and PD1-Vaxx, B-cell immuno-therapies designed to target specific tumor types.
They also have a pipeline of immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) that can be combined with standard care and emerging immunotherapies like CAR T-cell therapies. Imugene collaborates with other companies and institutions to advance their research and deliver optimized clinical benefits to patients. With a strong leadership team and a commitment to scientific excellence, Imugene is at the forefront of cancer immunotherapy.
Contact Imugene to learn more about their groundbreaking treatments and join their mission to fight cancer
Company type
Public Company
Year founded
2013
Company size
51-200 employees
Allogeneic CAR T-cell therapy
CD19-targeting cell therapy
B-cell malignancy clinical trials
Cancer immunotherapy development
